Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 21 of 25
<< Start
< Prev
16
17
18
19
20
21
22
23
24
25
Next >
End >>
30.03.2010
The Leukemia & Lymphoma Society and Avila Therapeutics Enter Partnership to Accelerate Development of AVL-292 For Patients with Cell B Malignancies
Press Release
22.03.2010
Impressive report issued by Soleil Securities on Advent portfolio company Cellnovo
In The News
16.03.2010
4-Antibody announces long-term collaboration with Boehringer Ingelheim with a maximum value of EUR 177.5m (CHF 266m) for 4-Antibody
Press Release
10.02.2010
Biocartis acquires Philips Technology Platform for Automated DNA/RNA Molecular Diagnostic Testing
Press Release
19.01.2010
AMT submits its lead product Glybera® Application for Marketing Authorisation Application to EMA
Press Release
24.11.2009
Oxagen Limited Raises £16 Million in Series C Private Venture Capital Financing Led by Novartis Venture Funds
Press Release
03.11.2009
Avila presents data on its novel, orally-available protease inhibitor, AVL-181, demonstrating viral clearance of hepatitis C virus in preclinical models
Press Release
02.11.2009
Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody
Press Release
20.10.2009
Privately held CardiacAssist reports record revenues for nine-month financial results
Press Release
15.10.2009
Biocartis raises €10 million in Series A financing round
Press Release
©2022 Advent Life Sciences